KPV: The Anti-Inflammatory Tail of a Hormone

The short version

KPV is one of the smallest peptides you will encounter — just three amino acids: lysine, proline, valine. It is the tail end (the final three residues, numbers 11-13) of a hormone called alpha-melanocyte-stimulating hormone, or alpha-MSH. The interesting detail is that this tail keeps the parent hormone's anti-inflammatory action but leaves behind its skin-darkening (pigment) effect ^[22].

Unlike the other compounds here, KPV is not primarily about building tissue — it is about calming the inflammation that can stall healing, and most of its research uses animal models of inflamed gut (colitis) ^[20]. Be clear-eyed about the evidence: there are no published human clinical trials of KPV. It is sold for laboratory research only, it is not an approved drug or supplement, and no human dose is listed on this page.

What it is

KPV is the linear tripeptide L-lysyl-L-prolyl-L-valine (Lys-Pro-Val), corresponding to residues 11-13 — the C-terminal tail — of alpha-MSH. Because it derives from a melanocortin hormone you will also see it written as alpha-MSH(11-13). Its defining property in the literature is that it preserves anti-inflammatory activity without the pigmentary (melanogenic) effect of the full hormone — which is why researchers describe it as an anti-inflammatory alternative to alpha-MSH, not a tanning agent ^[22]. KPV is a research peptide with no approved drug or supplement status in any major jurisdiction.

How it works

KPV dampens inflammation by suppressing two master inflammatory switches inside cells: the transcription factor NF-kB and the MAP-kinase signaling pathways. Quieting those switches reduces the output of pro-inflammatory messenger molecules (cytokines including IL-1beta and TNF-alpha) ^[20].

There is also a notable delivery advantage in the gut. KPV is small enough to be carried directly into intestinal lining cells by a di/tripeptide transporter called PepT1 (gene SLC15A1) — and PepT1 is upregulated specifically in inflamed intestinal tissue, so the transport route is most active exactly where the inflammation is ^[20]. At nanomolar concentrations, KPV taken up this way reduced NF-kB and MAPK activation and lowered cytokine secretion in both epithelial and immune cells ^[20]. Notably, the anti-inflammatory effect persisted in mice lacking the MC1R receptor, confirming an MC1R-independent mechanism — it is not acting through the classic melanocortin receptor ^[21].

What the research shows

Mechanism in cells and mice. The foundational study demonstrated PepT1-mediated KPV uptake into human intestinal epithelial cell lines and Jurkat T cells, with nanomolar KPV inhibiting NF-kB and MAP-kinase signaling and reducing pro-inflammatory cytokine secretion; orally administered KPV reduced the severity of two chemically induced colitis models (DSS and TNBS) in mice ^[20].

Colitis recovery. In murine colitis, KPV produced earlier recovery, stronger body-weight regain, reduced colonic inflammatory infiltrate and lower myeloperoxidase activity (a marker of immune-cell activity); the effect was retained in MC1R-deficient mice, confirming the MC1R-independent route ^[21].

Targeted delivery. Because free KPV is fragile and rapidly broken down, much recent work focuses on delivery. Orally administered hyaluronic-acid-functionalized nanoparticles carrying KPV, embedded in a chitosan/alginate hydrogel, reduced colitis severity more effectively than non-targeted formulations, downregulating TNF-alpha and accelerating mucosal healing ^[19]. A 2024 PepT1-targeted nanodrug co-assembling KPV with an immunosuppressant improved both acute and chronic colitis in mice, outperforming either agent alone ^[18].

Breadth review. A comprehensive review of alpha-MSH and related tripeptides describes KPV and relatives showing protective effects across fever, dermatitis, vasculitis, fibrosis, ocular, gastrointestinal, brain, airway, arthritic and organ-injury models, delineating KPV specifically as the anti-inflammatory alternative that lacks pigmentary action ^[22].

Reported effects, cautions & safety

The cautions for KPV start with one overriding fact — the evidence is entirely preclinical:

• No human trials. There are no published human clinical trials of KPV; the entire efficacy base is in vitro and animal (chiefly mouse colitis), so human dosing, efficacy and safety are unestablished ^[20].
• Fragility and no human PK. Free KPV is a small, peptidase-labile tripeptide with no validated human pharmacokinetics — exactly why so much of the recent research focuses on formulation strategies to keep it intact long enough to act ^[19].
• Marketing runs ahead of evidence. Promotion of KPV for gut health, skin or general anti-inflammatory use is not supported by a clinical evidence base; the data are mechanistic and preclinical.
• Not a tanning peptide. Although KPV comes from alpha-MSH, it should not be confused with melanocortin agonists used for pigmentation; its defining property is anti-inflammatory action without pigment effect ^[22].
• No specific WADA classification. KPV is not specifically named on the WADA Prohibited List, but as a non-approved peptide it should be treated cautiously in any sport context.

No community-anecdote reports are compiled for KPV as a standalone compound in this site's source material.

Where it fits in recovery research

KPV is the outlier on this site, usefully. Where BPC-157, TB-500 and GHK-Cu build tissue or drive cell movement, KPV works the other side of repair — turning down the inflammatory noise that can prevent a wound from closing ^[20]. Its evidence is the most uniformly preclinical of the four singles (no human trials), but its mechanism is among the most precisely mapped, down to the specific PepT1 transporter and an MC1R-independent pathway ^[21]. It also appears as one component of KLOW, where its gut-quieting role is paired with three repair-oriented partners. See the compare page for the full side-by-side.